06086.HK
Fangzhou Inc.
HKSE · Consumer Cyclical · Drug Manufacturers - General · CN
HKD 1.00
−0.99%Year over year
Reported trailing growth
- Revenue
- +34.1%
- EBITDA
- -23.7%
- EBIT
- +170.7%
- EPS
- +132.8%
- Free cash flow
- +140.5%
- Operating cash flow
- +125.2%
Forward estimates
Based on analyst estimates
- Revenue
- -30.3%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +17.0%
- EBITDA
- +104.7%
- EBIT
- +101.7%
- Net income
- +101.4%
- EPS
- +101.0%
- Free cash flow
- +98.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026